Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response evaluation of PEG-rhGH in children with short stature
ChiCTR2500097861Phase 4Not yet recruiting
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of peg-somatropin in growth hormone deficiency (GHD) and Idiopathic Short Stature (ISS) (3 arms), sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoints: Height at 12 months and Growth velocity at 12 months. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
peg-somatropin
03
Conditions
growth hormone deficiency (GHD)Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on ChiCTR2500097861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097861.